0000899243-22-034898.txt : 20221103 0000899243-22-034898.hdr.sgml : 20221103 20221103161543 ACCESSION NUMBER: 0000899243-22-034898 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20221101 FILED AS OF DATE: 20221103 DATE AS OF CHANGE: 20221103 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Gross Paul Edward CENTRAL INDEX KEY: 0001766329 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-35347 FILM NUMBER: 221358213 MAIL ADDRESS: STREET 1: 5500 FLATIRON PARKWAY, SUITE 100 CITY: BOULDER STATE: CO ZIP: 80302 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Clovis Oncology, Inc. CENTRAL INDEX KEY: 0001466301 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 900475355 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 5500 FLATIRON PARKWAY STREET 2: SUITE 100 CITY: BOULDER STATE: CO ZIP: 80301 BUSINESS PHONE: (303) 625-5000 MAIL ADDRESS: STREET 1: 5500 FLATIRON PARKWAY STREET 2: SUITE 100 CITY: BOULDER STATE: CO ZIP: 80301 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2022-11-01 0 0001466301 Clovis Oncology, Inc. CLVS 0001766329 Gross Paul Edward C/O CLOVIS ONCOLOGY, INC. 5500 FLATIRON PARKWAY, SUITE 100 BOULDER CO 80301 0 1 0 0 See Remarks Common Stock 2022-11-01 4 M 0 5623 A 98435 D Common Stock 2022-11-02 4 S 0 2595 0.9829 D 95840 D Common Stock 2022-11-01 4 M 0 4625 A 100465 D Common Stock 2022-11-02 4 S 0 2135 0.9829 D 98330 D Restricted Stock Units 2022-11-01 4 M 0 5623 0.00 D Common Stock 5623 5625 D Restricted Stock Units 2022-11-01 4 M 0 4625 0.00 D Common Stock 4625 23125 D Each Restricted Stock Unit represents the right to receive one share of Common Stock. Represents the shares automatically sold by the reporting person pursuant to an election to satisfy tax withholding obligations in connection with the vesting of the Restricted Stock Units listed in Table II. This sale does not represent a discretionary trade by the reporting person. This transaction was executed in multiple trades at prices ranging from $0.9621 to $0.9830. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. On February 1, 2019, the reporting person was granted 89,982 Restricted Stock Units. 25% of such Restricted Stock Units vested on February 1, 2020, and the remainder vests in substantially equal installments over the 12 quarters immediately following such date. On January 31, 2020, the reporting person was granted 74,000 Restricted Stock Units. 25% of such Restricted Stock Units vested on February 1, 2021, and the remainder vests in substantially equal installments over the 12 quarters immediately following such date. Executive Vice President and General Counsel /s/ Paul Gross 2022-11-02